Illumina, Inc. (ILMN): Price and Financial Metrics
Illumina, Inc. (ILMN)
Today's Latest Price: $376.35 USD
Updated Jan 15 4:00pm
Add ILMN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ILMN Stock Summary
- Illumina Inc's market capitalization of $54,171,840,000 is ahead of 95.69% of US-listed equities.
- Price to trailing twelve month operating cash flow for ILMN is currently 48.5, higher than 90.21% of US stocks with positive operating cash flow.
- ILMN's price/sales ratio is 16.73; that's higher than the P/S ratio of 88.66% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are VMW, NTES, KLAC, EW, and ADI.
- ILMN's SEC filings can be seen here. And to visit Illumina Inc's official web site, go to www.illumina.com.
ILMN Stock Price Chart Interactive Chart >
ILMN Price/Volume Stats
| Current price | $376.35 | 52-week high | $404.20 |
| Prev. close | $371.04 | 52-week low | $196.78 |
| Day low | $370.03 | Volume | 1,873,400 |
| Day high | $396.00 | Avg. volume | 1,202,190 |
| 50-day MA | $340.29 | Dividend yield | N/A |
| 200-day MA | $339.75 | Market Cap | 54.95B |
Illumina, Inc. (ILMN) Company Bio
Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $376.35 | $103.59 | -72% |
We started the process of determining a valid price forecast for Illumina Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Illumina Inc ranked in the 24th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 72%. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:
- The company's debt burden, as measured by earnings divided by interest payments, is 19.8; that's higher than 82.45% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 13.63% of the free cash flow producing stocks we're observing.
- ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.85% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -73% |
| 1% | -72% |
| 2% | -72% |
| 3% | -72% |
| 4% | -72% |
| 5% | -71% |
DHR, ICUI, WAT, CDNA, and CNC can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...